Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;31(9):1699-706.
doi: 10.3174/ajnr.A2161. Epub 2010 Jun 25.

Differentiation among glioblastoma multiforme, solitary metastatic tumor, and lymphoma using whole-tumor histogram analysis of the normalized cerebral blood volume in enhancing and perienhancing lesions

J H Ma  1 , H S Kim, N-J Rim, S-H Kim, K-G Cho
Affiliations

Differentiation among glioblastoma multiforme, solitary metastatic tumor, and lymphoma using whole-tumor histogram analysis of the normalized cerebral blood volume in enhancing and perienhancing lesions

J H Ma et al. AJNR Am J Neuroradiol. 2010 Oct.

Abstract

Background and purpose: The histogram method has been shown to demonstrate heterogeneous morphologic features of tumor vascularity. This study aimed to determine whether whole-tumor histogram analysis of the normalized CBV for contrast-enhancing lesions and perienhancing lesions can differentiate among GBMs, SMTs, and lymphomas.

Materials and methods: Fifty-nine patients with histopathologically confirmed GBMs (n = 28), SMTs (n = 22), or lymphomas (n = 12) underwent conventional MR imaging and dynamic susceptibility contrast-enhanced imaging before surgery. Histogram distribution of the normalized CBV was obtained from whole-tumor voxels in contrast-enhancing lesions and perienhancing lesions. The HW, PHP, and MV were determined from histograms. One-way ANOVA was used initially to test the overall equality of mean values for each type of tumor. Subsequently, posttest multiple comparisons were performed.

Results: For whole-tumor histogram analyses for contrast-enhancing lesions, only PHP could differentiate among GBMs (4.79 ± 1.31), SMTs (3.32 ± 1.10), and lymphomas (2.08 ± 0.54). The parameters HW and MV were not significantly different between GBMs and SMTs, whereas the 2 histogram parameters were significantly higher in GBMs and SMTs compared with lymphomas. For the analyses of perienhancing lesions, only MV could differentiate among GBMs (1.90 ± 0.26), SMTs (0.80 ± 0.21), and lymphomas (1.27 ± 0.34). HW and PHP were not significantly different between SMTs and lymphomas.

Conclusions: Using a whole-tumor histogram analysis of normalized CBV for contrast-enhancing lesions and perienhancing lesions facilitates differentiation of GBMs, SMTs and lymphomas.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
The schema of histogram distribution in a patient with GBM. A and B, Axial postcontrast T1-weighted image (A) and the normalized CBV map (B) show typical findings of GBM. C, Three histogram parameters are defined as HW, PHP, and MV.
Fig 2.
Fig 2.
MR images and dynamic susceptibility contrast-enhanced imaging histograms in patients with GBM (A), metastatic tumor (B), and lymphoma (C).
Fig 3.
Fig 3.
Box-and-whisker plots of 6 histogram parameters for 3 pathologic groups of solitary enhancing brain lesions. A, HW in contrast-enhancing lesions. B, PHP in contrast-enhancing lesions. C, MV in contrast-enhancing lesions. D, HW in perienhancing lesions. E, PHP in perienhancing lesions. F, MV in perienhancing lesions.
Fig 4.
Fig 4.
Comparison of ROC curves of 6 histogram parameters in the contrast-enhancing lesions and perienhancing lesions for differentiating GBM and SMT (A), GBM and lymphoma (B), and SMT and lymphoma (C).
See this image and copyright information in PMC

References

    1. Surawicz TS, McCarthy BJ, Kupelian V, et al. . Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro Oncol 1999; 1: 14– 25 - PMC - PubMed
    1. Cha S, Lupo JM, Chen MH, et al. . Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007; 28: 1078– 84 - PMC - PubMed
    1. Herrlinger U, Schabet M, Clemens M, et al. . Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma. Acta Neurol Scand 1998; 97: 257– 64 - PubMed
    1. Ling SM, Roach M, Larson DA, et al. . Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus: ten years of treatment experience at the University of California San Francisco. Cancer 1994; 73: 2570– 82 - PubMed
    1. Reni M, Ferreri AJ, Garancini MP, et al. . Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997; 8: 227– 34 - PubMed

MeSH terms